Role of IL-4 and Th2 responses in allograft rejection and tolerance

Current Opinion in Organ Transplantation

Volumn 14, Issue 1, 2009, Pages 16-22

  Tay, Szun Szun ^a   Plain, Karren M ^b,c   Bishop, G Alex ^a,c  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Alternative; Macrophage; Receptor; Th2 cytokines

Indexed keywords

ARGININE; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA;

ALLOGRAFT; CYTOKINE PRODUCTION; GRAFT REJECTION; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; MACROPHAGE ACTIVATION; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; ALLOTRANSPLANTATION; ANIMAL; GRAFT SURVIVAL; IMMUNOLOGY; INFLAMMATION; METABOLISM; ORGAN TRANSPLANTATION; SIGNAL TRANSDUCTION; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

ANIMALS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; INFLAMMATION; INTERLEUKIN-4; MACROPHAGE ACTIVATION; ORGAN TRANSPLANTATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TH2 CELLS; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 67649213521     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32831ebdf5     Document Type: Review

References (79)

1. Paul WE. Interleukin 4: a prototypic immunoregulatory lymphokine. Blood 1991; 77:1859-1870.
2. Nelms K, Keegan AD, Zamorano J, et al. The IL-4 receptor: signaling mechanisms and biologic functions. Ann Rev Immunol 1999; 17:701-738. (Pubitemid 29241138)
3. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136:2348-2357.
4. Coffman RL, Varkila K, Scott P, Chatelain R. Role of cytokines in the differentiation of CD4+ T-cell subsets in vivo. Immunol Rev 1991; 123:189-207.
5. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997; 89:587-596. (Pubitemid 27511769)
6. LaPorte SL, Juo ZS, Vaclavikova J, et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 2008; 132:259-272. The molecular structures of the type I and type II receptors for IL-4 and IL-13 were solved, and the affinity of the receptors was examined. The ability of IL-4 to bind to both receptors was established on a structural level, and the implications for signalling were discussed.
7. Akaiwa M, Yu B, Umeshita-Suyama R, et al. Localization of human interleukin 13 receptor in nonhaematopoietic cells. Cytokine 2001; 13:75-84. (Pubitemid 32579312)
8. Andrews AL, Holloway JW, Holgate ST, Davies DE. IL-4 receptor {alpha} is an important modulator of IL-4 and IL-13 receptor binding: Implications for the development of therapeutic targets. J Immunol 2006; 176:7456-7461.
9. Strom TB, Roy-Chaudhury P, Manfro R, et al. The Th1/Th2 paradigm and the allograft response. Curr Opin Immunol 1996; 8:688-693.
10. Piccotti JR, Chan SY, VanBuskirk AM, et al. Are Th2 helper T lymphocytes beneficial, deleterious, or irrelevant in promoting allograft survival? Transplantation 1997; 63:619-624.
11. Donckier V, Wissing M, Bruyns C, et al. Critical role of interleukin 4 in the induction of neonatal transplantation tolerance. Transplantation 1995; 59:1571-1576.
12. Gao QL, Chen NX, Rouse TM, Field EH. The role of interleukin-4 in the induction phase of allogeneic neonatal tolerance. Transplantation 1996; 62:1847-1854.
13. Chen N, Gao Q, Field EH. Prevention of Th1 response is critical for tolerance. Transplantation 1996; 61:1076-1083. (Pubitemid 26120259)
14. Inoue Y, Konieczny BT, Wagener ME, et al. Failure to induce neonatal tolerance in mice that lack both IL-4 and IL-13 but not in those that lack IL-4 alone. J Immunol 2001; 167:1125-1128. (Pubitemid 32660874)
15. Nickerson P, Zheng XX, Steiger J, et al. Prolonged islet allograft acceptance in the absence of interleukin 4 expression. Transpl Immunol 1996; 4:81-85. (Pubitemid 26167069)
16. Lakkis FG, Konieczny BT, Saleem S, et al. Blocking the CD28-B7 T cell costimulation pathway induces long term cardiac allograft acceptance in the absence of IL-4. J Immunol 1997; 158:2443-2448. (Pubitemid 127470032)
17. Ritter T, Risch K, Schroder G, et al. Intragraft overexpression of interleukin-4 is neither sufficient nor essential for tolerance induction to cardiac allografts in a high-responder strain combination. Transplantation 1999; 68:1427-1431.
18. Bushell A, Niimi M, Morris PJ, Wood KJ. Evidence for immune regulation in the induction of transplantation tolerance: a conditional but limited role for IL-4. J Immunol 1999; 162:1359-1366. (Pubitemid 29307006)
19. Plain KM, Fava L, Spinelli A, et al. Induction of tolerance with nondepleting anti-CD4 monoclonal antibodies is associated with down-regulation of TH2 cytokines. Transplantation 1997; 64:1559-1567. (Pubitemid 28047383)
20. Hall BM, Plain KM, Verma ND, et al. Transfer of allograft specific tolerance requires CD4+CD25+T cells but not interleukin-4 or transforming growth factor-beta and cannot induce tolerance to linked antigens. Transplantation 2007; 83:1075-1084.
21. Hall BM, Fava L, Chen J, et al. Anti-CD4 monoclonal antibody-induced tolerance to MHC-incompatible cardiac allografts maintained by CD4+ suppressor T cells that are not dependent upon IL-4. J Immunol 1998; 161:5147-5156. (Pubitemid 28519071)
22. Chen ZK, Cobbold SP, Waldmann H, Metcalfe S. Amplification of natural regulatory immune mechanisms for transplantation tolerance. Transplantation 1996; 62:1200-1206. (Pubitemid 27008539)
23. Davies JD, Martin G, Phillips J, et al. T cell regulation in adult transplantation tolerance. J Immunol 1996; 157:529-533. (Pubitemid 26231352)
24. - regulatory cells mediate dominant transplantation tolerance. J Immunol 2002; 168:5558-5565.
25. Ke B, Ritter T, Kato H, et al. Regulatory cells potentiate the efficacy of IL-4 gene transfer by up-regulating Th2-dependent expression of protective molecules in the infectious tolerance pathway in transplant recipients. J Immunol 2000; 164:5739-5745. (Pubitemid 30389816)
26. Shi Q, Wang D, Hadley GA, et al. Abrogation of recurrent autoimmunity in the NOD mouse: a critical role for host interleukin 4. Surgery 2006; 140:281-288. (Pubitemid 44176070)
27. He XY, Chen J, Verma N, et al. Treatment with interleukin-4 prolongs allogeneic neonatal heart graft survival by inducing T helper 2 responses. Transplantation 1998; 65:1145-1152. (Pubitemid 28224329)
28. Davidson C, Verma ND, Robinson CM, et al. IL-13 prolongs allograft survival: association with inhibition of macrophage cytokine activation. Transpl Immunol 2007; 17:178-186. Systemic IL-13 treatment, like IL-4 [23], delayed rejection of neonatal cardiac allografts in adult rats. Unlike IL-4, IL-13 did not act on T cells nor modulate Th1/Th2 balance but appeared to inhibit dendritic cell and macrophage activation.
29. Levings MK, Schrader JW. IL-4 inhibits the production of TNF-alpha and IL-12 by STAT6-dependent and -independent mechanisms. J Immunol 1999; 162:5224-5229.
30. Stout RD, Jiang C, Matta B, et al. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 2005; 175:342-349. (Pubitemid 40884337)
31. Erwig LP, Kluth DC, Walsh GM, Rees AJ. Initial cytokine exposure determines function of macrophages and renders them unresponsive to other cytokines. J Immunol 1998; 161:1983-1988.
32. Wang Y, Wang YP, Zheng G, et al. Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int 2007; 72:290-299. Injection of macrophages stimulated with IL-4 and IL-13 reduced severity of adriamycin-induced glomerular injury for up to 3 weeks, whereas injection of LPS-activated macrophages worsened disease. These findings support the concept that specific macrophage subsets can have dominant anti-inflammatory properties.
33. Kluth DC, Ainslie CV, Pearce WP, et al. Macrophages transfected with adenovirus to express IL-4 reduce inflammation in experimental glomerulonephritis. J Immunol 2001; 166:4728-4736.
34. Furukawa H, Oshima K, Tung T, et al. Liposome-mediated combinatorial cytokine gene therapy induces localized synergistic immunosuppression and promotes long-term survival of cardiac allografts. J Immunol 2005; 174:6983-6992. (Pubitemid 40705663)
35. Sandovici M, Deelman LE, van Goor H, et al. Adenovirus-mediated interleukin-13 gene therapy attenuates acute kidney allograft injury. J Gene Med 2007; 9:1024-1032. (Pubitemid 350286407)
36. Ke B, Shen XD, Lassman CR, et al. Cytoprotective and antiapoptotic effects of IL-13 in hepatic cold ischemia/reperfusion injury are heme oxygenase-1 dependent. Am J Transplant 2003; 3:1076-1082. (Pubitemid 37064546)
37. Haeryfar SM, Lan Z, Leon-Ponte M, et al. Prolongation of cardiac allograft survival by rapamycin and the invariant natural killer T cell glycolipid agonist OCH. Transplantation 2008; 86:460-468.
38. Morita Y, Yang J, Gupta R, et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001; 107:1275-1284. (Pubitemid 32494544)
39. Sriram U, Biswas C, Behrens EM, et al. IL-4 suppresses dendritic cell response to type I interferons. J Immunol 2007; 179:6446-6455.
40. Webb DC, Cai Y, Matthaei KI, Foster PS. Comparative roles of IL-4, IL-13, and IL-4R{alpha} in dendritic cell maturation and CD4+ Th2 cell function. J Immunol 2007; 178:219-227. (Pubitemid 46033604)
41. Hochrein H, O'Keeffe M, Luft T, et al. Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J Exp Med 2000; 192:823-833. (Pubitemid 30737589)
42. Kaneko K, Wang Z, Kim SH, et al. Dendritic cells genetically engineered to express IL-4 exhibit enhanced IL-12p70 production in response to CD40 ligation and accelerate organ allograft rejection. Gene Ther 2003; 10:143-152. (Pubitemid 36582586)
43. Biedermann T, Zimmermann S, Himmelrich H, et al. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat Immunol 2001; 2:1054-1060. (Pubitemid 33069501)
44. Morris SC, Orekhova T, Meadows MJ, et al. IL-4 induces in vivo production of IFN-gamma by NK and NKT cells. J Immunol 2006; 176:5299-5305.
45. Togashi Y, Chamoto K, Wakita D, et al. Natural killer T cells from interleukin-4-deficient mice are defective in early interferon-gamma production in response to alpha-galactosylceramide. Cancer Sci 2007; 98:721-725. The NKT cell ligand alpha-galactosylceramide stimulates both IFN-γ and IL-4 production in NKT cells from wild-type mice; however, there is a paradoxical lack of early IFN-γ production in IL-4-deficient mice. These results show that contrary to its effects on T cells, in which it suppresses IFN-γ production, it is necessary for early production of IFN-γ in NKT cells.
46. Maliszewski CR, Morrissey PJ, Fanslow WC, et al. Delayed allograft rejection in mice transgenic for a soluble form of the IL-4 receptor. Cell Immunol 1992; 143:434-448.
47. Vanbuskirk AM, Wakely ME, Orosz CG. Transfusion of polarized Th2-like cell populations into SCID mouse cardiac allograft recipients results in acute allograft rejection. Transplantation 1996; 62:229-238.
48. Barbara JA, Turvey SE, Kingsley CI, et al. Islet allograft rejection can be mediated by CD4+, alloantigen experienced, direct pathway T cells of TH1 and TH2 cytokine phenotype. Transplantation 2000; 70:1641-1649.
49. Piccotti JR, Chan SY, Goodman RE, et al. IL-12 antagonism induces T helper 2 responses, yet exacerbates cardiac allograft rejection: evidence against a dominant protective role for T helper 2 cytokines in alloimmunity. J Immunol 1996; 157:1951-1957.
50. Le Moine A, Flamand V, Demoor FX, et al. Critical roles for IL-4, IL-5, and eosinophils in chronic skin allograft rejection. J Clin Invest 1999; 103:1659-1667. (Pubitemid 29534360)
51. Braun MY, Desalle F, Le Moine A, et al. IL-5 and eosinophils mediate the rejection of fully histoincompatible vascularized cardiac allografts: regulatory role of alloreactive CD8+ T lymphocytes and IFN-gamma. Eur J Immunol 2000; 30:1290-1296. (Pubitemid 30311957)
52. Poulin LF, Richard M, Le Moine A, et al. Interleukin-9 promotes eosinophilic rejection of mouse heart allografts. Transplantation 2003; 76:572-577. (Pubitemid 37013265)
53. Wang C, Li J, Cordoba SP, et al. Posttransplant IL-4 treatment converts rat liver allograft tolerance to rejection. Transplantation 2005; 79:1116-1120. (Pubitemid 40664007)
54. Guillot C, Coathalem H, Chetritt J, et al. Lethal hepatitis after gene transfer of IL-4 in the liver is independent of immune responses and dependent on apoptosis of hepatocytes: a rodent model of IL-4-induced hepatitis. J Immunol 2001; 166:5225-5235. (Pubitemid 32280739)
55. Buonocore S, Flamand V, Goldman M, Braun MY. Bone marrow-derived immature dendritic cells prime in vivo alloreactive T cells for interleukin-4-dependent rejection of major histocompatibility complex class II antigen-disparate cardiac allograft. Transplantation 2003; 75:407-413. (Pubitemid 36222970)
56. Keane MP, Gomperts BN, Weigt S, et al. IL-13 is pivotal in the fibro-obliterative process of bronchiolitis obliterans syndrome. J Immunol 2007; 178:511-519. Bronchoalveolar lavage fluid from lung transplant patients with bronchiolitis obliterans, a fibro-occlusive disease associated with chronic rejection showed significantly increased profibrotic activity in vitro. This finding was associated with increased IL-13 and could be neutralized with antibodies to IL-13. The role of IL-13 in BOS was confirmed and extended in a mouse model.
57. Uboldi de Capei M, Dametto E, Fasano ME, et al. Cytokines and chronic rejection: a study in kidney transplant long-term survivors. Transplantation 2004; 77:548-552. (Pubitemid 38282810)
58. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3:23-35.
59. Hesse M, Modolell M, La Flamme AC, et al. Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism. J Immunol 2001; 167:6533-6544. (Pubitemid 33081589)
60. Holan V, Pindjakova J, Krulova M, et al. Production of nitric oxide during graft rejection is regulated by the Th1/Th2 balance, the arginase activity, and L-arginine metabolism. Transplantation 2006; 81:1708-1715. (Pubitemid 43948305)
61. Famulski KS, Sis B, Billesberger L, Halloran PF. Interferon-gamma and donor MHC class I control alternative macrophage activation and activin expression in rejecting kidney allografts: a shift in the Th1-Th2 paradigm. Am J Transplant 2008; 8:547-556. This study examined the basis for IFN-g-induced MHC class I protection against accelerated graft necrosis dependent on perforin and granzymes. Microarray analysis showed multiple markers of alternative macrophage activation were associated with accelerated rejection. Of interest, alternative activation appeared to be independent of IL-4 and IL-13 and due to increased expression of activins.
62. Liu H, Drew P, Gaugler AC, et al. Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway. Am J Transplant 2005; 5:1256-1263. (Pubitemid 40839413)
63. Hall BM, Jelbart ME, Gurley KE, Dorsch SE. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. Mediation of specific suppression by T helper/inducer cells. J Exp Med 1985; 162:1683-1694.
64. Hall BM, Pearce NW, Gurley KE, Dorsch SE. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine III. Further characterisation of the CD4+ suppressor cell and its mechanisms of action. J Exp Med 1990; 171:141-157. (Pubitemid 20040605)
65. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003; 3:253-257.
66. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057-1061. (Pubitemid 36222930)
67. + regulatory T cells. Nat Immunol 2003; 4:330-336.
68. Thornton AM. Signal transduction in CD4+CD25+ regulatory T cells: CD25 and IL-2. Front Biosci 2006; 11:921-927.
69. Thornton AM, Piccirillo CA, Shevach EM. Activation requirements for the induction of CD4+CD25+ T cell suppressor function. Eur J Immunol 2004; 34:366-376.
70. Maerten P, Shen C, Bullens DM, et al. Effects of interleukin 4 on CD25+CD4+ regulatory T cell function. J Autoimmun 2005; 25:112-120.
71. Pace L, Pioli C, Doria G. IL-4 modulation of CD4+CD25+ T regulatory cell-mediated suppression. J Immunol 2005; 174:7645-7653.
72. + Treg suppressive function.
73. + Tregs activated in response to alloantigen stimulation, depending on the Th1 or Th2 cytokine environment. Both these subsets were shown to suppress rejection and could be identified in long-survivng tolerant hosts.
74. Skapenko A, Kalden JR, Lipsky PE, Schulze-Koops H. The IL-4 receptor alpha-chain-binding cytokines, IL-4 and IL-13, induce forkhead box P3-expressing CD25+CD4+ regulatory T cells from CD25-CD4+ precursors. J Immunol 2005; 175:6107-6116.
75. + precursors.
76. Mantel PY, Kuipers H, Boyman O, et al. GATA3-driven Th2 responses inhibit TGF-beta1-induced FOXP3 expression and the formation of regulatory T cells. PLoS Biol 2007; 5:e329. This paper showed that the mechanism of Th2-mediated and IL-4-mediated cross-regulation of inducible Treg development is directly related to GATA-3, the transcription factor associated with Th2 commitment, which binds to the Foxp3 promoter.
77. Cosmi L, Liotta F, Angeli R, et al. Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines. Blood 2004; 103:3117-3121. (Pubitemid 38451689)
78. Stummvoll GH, DiPaolo RJ, Huter EN, et al. Th1, Th2, and Th17 effector T cell-induced autoimmune gastritis differs in pathological pattern and in susceptibility to suppression by regulatory T cells. J Immunol 2008; 181:1908-1916. This study showed that in a single model system, Th1, Th2 and Th17 helper cells could be effectors of immunopathology, with differing histological profiles. Further, that natural Tregs have variable capacity to suppress the different subsets of Th cells.
79. Taylor JJ, Mohrs M, Pearce EJ. Regulatory T cell responses develop in parallel to Th responses and control the magnitude and phenotype of the Th effector population. J Immunol 2006; 176:5839-5847.